Author:
Cook Leah M.,Shay Gemma,Aruajo Arturo,Lynch Conor C.
Publisher
Springer Science and Business Media LLC
Reference143 articles.
1. Keller, E. T., & Brown, J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 91(4), 718–729.
2. Fizazi, K., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813–822.
3. Choudhury, A. D., & Kantoff, P. W. (2012). New agents in metastatic prostate cancer. Journal of the National Comprehensive Cancer Network, 10(11), 1403–1409.
4. Anonymous. (2013). FDA approves radiopharmaceutical for metastatic prostate cancer. Cancer Discovery, 3(7), OF1.
5. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献